Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On the whole, I agree with you and easycomeandgo. The current PPS reflects all available information and we can assume that no assumptions have been ignored by the institutions that hold the stock. Undoubtedly, the market's main concern is growth beyond 2028. However, I think that the information Halo provided during the presentation in january contained some significant uncertainties, some of them regarding the pending patents. If and when those patents are granted, those uncertainties will be removed and that should alleviate some, certainly not all, of the concern with future growth.
We do have three potential approvals in the next six months or so, Hytrulo for CIDP, Tecentriq and Ocrevus. If they all get approved, that should also help. On the other hand, I don't think the market is particularly excited about any of them. I think investors are concerned that Darzalex was the exception to the rule and that none of the Enhanze products in development will do nearly as well. Of course, some of the products eventually could exceed expectations and the stock price will reflect that. In the meantime, it seems that only substantial new deals and the acquisition of a strong technology platform can restore confidence and really turn things around for Halo.
Halo's YTD performance matches exactly the S&P 500. It's underperformed the S&P 500 at 6 months and 1 year.
https://finance.yahoo.com/quote/HALO/chart?nn=1#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--
I agree that the patents are material to future income, but I believe that this is baked into the current price and we are not going to break out of the range unless there is hope for future growth. This concern over the lack of new deals is taking the place of the patent cliff worries of recent years and will get more prominently featured in analyst papers going forward.
I think that, with almost all shares in professional hands, no possible assumptions go ignored and that the price reflects that. This can be taken for certain after the management presentation on intellectual property durability. This is disquieting. I doubt that elementary analysis based on multiples, etc., is ignored by institutions. There is no scarcity of unfulfilled enthusiastic published research, either. I only hold what I do because it is short term. Probably not the best of reasons. The market seems expensive to me.
Oh, thank you very much for showing me how wealth is not created. I always yearn for such highly regarded pointers on that. Expert is as expert does.
I am assuming that if all patents are granted, Halo gets an additional 7 years of royalties on Tecentriq and possibly 10 years on Hytrulo, plus 3 years without reduction in royalties for Ocrevus. Probably not enough to reach new highs but maybe enough to get to $50, especially if it happens soon. Of course, if no new deals are signed in ‘24, we are in serious trouble. They have already destroyed their credibility, it’s going to be really hard to regain investors’ trust if they don’t deliver something soon.
“Evil”?!!! Who said anything about management being “evil”?!!!
I’m sorry you regularly resort to hyperbole and see everything at such black and white extremes. This kind of emotional thinking is not how wealth is created.
It is perfectly reasonable to ask for more from management when they don’t deliver on certain promises (e.g. 3 deals for 2023). It is also reasonable to lean on them for selling (as opposed to buying some) shares when many including the management opine that the stock is undervalued.
Despite these shortcomings, a reasonable investor can also simultaneously appreciate the underlying successful technology that has made Halozyme highly profitable and a EBITA growth machine.
Just because they failed on a some fronts, it does not make them “evil” or “self-destructive.” It just means they can do better. Even the best C-suites make some mistakes at times. Best case scenario they learn from their mistakes and worst case scenario, investor can push (or at least express a need) for a change in leadership (I for one would be happy with changes). However, none of this makes the management “evil” or the underlying successful technology “un-investable” as you claim.
If you thought this way, you would have missed the recent 30% run from low $30’s to $40 and the previous runs from single digits to all time highs. Some of us were able to see the value of Enhanze despite the management failures in 2023 and loaded up even more in the low 30’s. I wrote on this board that Halozyme is a cash generating machine despite the management (not because of it) and still believe this.
Halozyme will continue to grow EBITA and is undervalued based on the already-approved Enhanze products. The stock will be perform quite well even without new deals. However, some of us (including me) would like to see even more with new deals, insider buys and better communication.
There is no indication when patents will be granted, but I don't think it will move the needle outside of the current rangebound limits at all. By the way, we've reached the end of the quarter with yet another goose egg for new deals. I'm starting to think that we are being actively lied to when HALO trumpets all the interest in partnerships that are supposedly percolating.
Probably not. You can’t blame someone for cashing in stock. It’s not like he’s selling into major strength. He’s not timing this just selling to pick up some cash. Maybe he wants a vacation home. I never look at program insider selling as a major negative. There hasn’t been any insider buying in a long time which concerns me a little bit but the buybacks can be looked at as an indirect way of insider buying I guess.
On another note I think that it takes at least a couple years to integrate an acquisition so we’ll see if it was money well spent soon enough. Certainly looks like it’s been accretive so far not that much.
I’m not a big fan of companies that over hype their stock with BS announcements so lack of announcements doesn’t bother me as much as it does others in this thread. There seems to be a lot of positive stuff going on just not a lot of PR. That being said if you call the company they should call back. No response is not acceptable.
Fantastic tweet from today:
“I ran a screener of
ROIC 3yr Average >20%
FCF margin 3yr Average >15%
Revenue Growth >25%
The top 4 Results were
1) Nvidia $NVDA
(46% / 28% / 125%)
2) Booking Holdings $BKNG
(28% / 28% / 25%)
3)Arista Networks $ANET
(51% / 25% / 33%)
4)Halozyme $HALO
(42% / 47% / 25%)”
I took a closer look at the slides. There is a patent pending for Tecentriq SC, Ocrevus SC and Hytrulo. Have they said when they expect these patents to be granted? If they do get granted, it'll make a significant difference.
It is not for me to reply to your question, it wasn’t addressed to me. Besides, I have no idea of what LaBarre is doing with his 10b-5. I can categorically say that a discussion is not easy. Reading the board, one comes away with the impression that for some unknown reason Halozyme management is intent on subverting the company’s stock, doing all they can, in defiance of its amazing promise, to knock any and all support from under it. They do not respond to belligerent interrogatives, corporate communications has taken upon itself to destroy the place of its employment, as they successfully did with the stellar company Antares. We probably need a resident shrink on the message board to attempt to deal with the persecution complex that rules. After reading the posts, one has to ask oneself, why on earth would I invest money in this thing? Good question, in any case… If management is so evil, why own the stock? Why, indeed…
Howee do you believe LaBarre has cancelled his 10b-5 selling plan?
I could not agree more.
Apparently, halozyme has hired a new PR firm to help them. But we have an IR problem as well. She does not respond to any form of communication.
Disappointing to say the least, and it makes one wonder why….
Viatris had a good presentation on Selatogrel yesterday. Pointing out the block buster potential of the drug-auto injector combo, but SADLY no mention of Halozyme supplying the auto injector. Then again, an investor would never know Halozyme is suppling the fully packaged Selatogrel-AI combo to Viatris, from any info Halozyme posts.
Idorsia would always have some good words for the Antares autoinjector in their presentations, and Antares had it in their presentations.
Why is that?
Even if the product is years away, why not let it be known another firm is interested in Halozyme auto-injector?
Is there a PR problem here or what? Should be paying me for investor updating PR services……….
If not for the little pictures in the presentations, one would never know the Halozyme connection. Sad.
https://investor.viatris.com/static-files/b01a07f3-e549-4522-8480-c31b359a6a4f
An EpiPen For Heart Attacks? Idorsia Launches Phase III Study Of Selatogrel
Pic of AI
https://scrip.citeline.com/SC144926/An-EpiPen-For-Heart-Attacks-Idorsia-Launches-Phase-III-Study-Of-Selatogrel
Pic of AI on ATRS presentation….
“SUPPLY fully packaged product at cost plus margin and ROYALTIES escalating to low double digits”
https://static.seekingalpha.com/uploads/sa_presentations/696/80696/original.pdf
Labarre should have plenty of money to pay tax on a few shares from the 20k per month he’s been selling. I think it’s a non event but fun to talk about anyway.
What a slender thread on which to hang one's hopes.
am I dreaming? Are my eyes deceiving me? Did LaBarre just convert some options and held onto the shares without selling a single one? This is welcomed news. https://d18rn0p25nwr6d.cloudfront.net/CIK-0001159036/465f2965-ed25-4e96-9042-6b62a53e45e3.pdf
Saw this in the morning when stock was up close to 2 bucks. Was kind of surprised it fizzled out. Oh well.
ARGX up as Roche/Chugai autoimmune disease drug disappoints in closely watched trial
BioPharma Dive· Industry Dive
Jonathan Gardner
Thu, Mar 21, 2024, 8:08 AM EDT2 min read
In This Article:
ROG.SW
-2.55%
AZN.L
+2.60%
An autoimmune disease drug from Roche and Chugai Pharmaceutical hit its main goal in a closely watched trial, but the results of the study, in a condition called myasthenia gravis, “did not reach our expectations,” the companies said Thursday.
Roche and Chugai have already brought the drug, known as Enspryng, to market for the rare eye condition neuromyelitis optica spectrum disorder. But the companies are working to expand its use elsewhere, including in myasthenia gravis, an autoimmune condition characterized by muscle weakness.
In recent years, myasthenia gravis has become a competitive area among drugmakers. AstraZeneca’s Soliris and Ultomiris are among the medicines available. More recently, Argenx’s Vyvgart became the first of a newer group of so-called FcRn inhibitors to get to market and has gotten off to a strong launch. Johnson & Johnson and Immunovant are advancing FcRn blockers as well.
Those drugs, though, faced a potential competitive threat from Enspryng. Recently published study results showed that tocilizumab, a drug that works similarly to Enspryng, might be an effective treatment for myasthenia gravis. That, in turn, had stoked fear among investors that the Enspyring trial could establish medicines like it, IL-6 inhibitors, as a “new standard-of-care” with “differentiated efficacy” and less frequent dosing than FcRn drugs, wrote Leerink Partners analyst Thomas Smith, in a note to clients Thursday.
The study tested Enspyrng in a trial that randomized 185 patients to receive the drug or a placebo over 24 weeks. The main goal was to outperform a placebo on a 24-point questionnaire.
Chugai revealed Thursday that Enspyring fell short of expectations on the “degree of clinical benefit” in the trial. The company didn’t provide further details, saving them instead for a medical meeting next month. It’ll continue developing Enspryng for other rare inflammatory conditions, such as thyroid eye disease and autoimmune encephalitis.
In the meantime, the effects of the findings rippled across to other developers. Argenx shared climbed 12% in Thursday morning trading, while Immunovant’s stock initially surged double digits before settling in to a smaller gain. Shares of Tourmaline Bio, which is developing an IL-6 drug for myasthenia gravis, fell nearly 40%.
Smith, of Leerink, expects the results “to be viewed as confirmation of FcRn’s current role as the preferred [target]” for the disease.
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
https://finance.yahoo.com/news/roche-autoimmune-disease-drug-disappoints-120800457.html?.tsrc=fin-srch
what’s going on with Halozyme’s IR? emails unanswered, voice messages unreturned, requests to speak with executives ignored, multiple new trials, and no PR. The investors deserve better.
They certainly make it confusing doing DD on their drugs, by continuously changing the names all the time.
It seems to be "N6LS BNAB" on the bottom of the pipeline, that is for some reason hidden, could not find the link from HALO home page.
The imagine in the partner column is from "Vaccine Research Center, National Institutes of Health."
https://halozyme.com/pipeline-build/
https://en.wikipedia.org/wiki/File:VRC-NIH_logo.png
Pace of new trials with Enhanze seems to be picking back up. 3 new ones just in the past week. Things were quiet for a while.
Another brand new study with Enhanze (first posted on 3/15/24).
Phase 1 GSK/Viiv trial + Enhanze on a brand new antiviral:
https://classic.clinicaltrials.gov/ct2/show/NCT06310551?term=Rhuph20&draw=4&rank=122
According to Table 2, the 10ml HVAI’s are in “development.”
Helen said that Halo’s 10ml HVAI is the first ever and no one else has done successfully in humans.
It seems that halo is ahead of
Thanks for the clarification!!
Halo is not the only firm with large volume AI, and they certainly were late to the game. Halo does seem to have the largest volume deliverable of 25 ml. No reason the other firms can not develop a HVAI, since some already have 10 ml injectors. But the other firms do not have Enhanze to pair with the HVAI.
"Table 2. An overview of investigational large-volume handheld autoinjectors with pre-filled syringes and cartridges exceeding 2.25 mL capacity."
https://www.tandfonline.com/doi/pdf/10.1080/17425247.2023.2219891
A little confusing, but in any case they are not giving up on SC injection, for reasons pointed out in the article, and the info in the patent, because SC allows for self-injection.
".............and additional evaluation of subcutaneous administration is planned. Unlike intramuscular injections, subcutaneous shots could potentially allow for self-administration.”
Skim through the patent posted earlier......They are looking at the two stage reconstitution injector.
35. A multi-compartment container, comprising a suspension comprising cabotegravir in one compartment, and a soluble hyaluronidase in a second compartment.
36. The multi-compartment container of claim 35 that is a syringe, comprising two compartments.
Much is happening in the AI (autoinjector) world and halozyme is far ahead of everyone else with it’s exquisite HVAI. Once we have a HVAI deal, there will be a buzz that will take share price to all time new highs.
Sorry to sound obstreperous, but there is nothing in that article that indicates Enhanz will be involved in the development of CAB-ULA in either iteration, whether subcu or IM.
Thanks for the Idorsia info. That was a deep dive!
Yes, ending with CAB200, but will continue on with SC CAB-ULA……….”Intramuscular CAB-ULA given every four months will now progress to late-stage PrEP and treatment trials, and additional evaluation of subcutaneous administration is planned. Unlike intramuscular injections, subcutaneous shots could potentially allow for self-administration.” Therefore the autoinjector......
And to earlier post....
Idorsia has a deal with ATRS to use their auto injector with Selatogrel, unless it was dropped with the Viatris deal, which would be unlikely with all the development and trials conducted using the ATRS AI.
https://www.idorsia.com/investors/news-and-events/media-releases/media-release-details?id=2206504
Well the last of my 3 posts today…..
FRom the article you posted recently
While AI's are mentioned in the articles, I didn't see any confirmation that they were ATRS products. Did I miss something?
Thanks, interestingly did not see selatogrel in the presentation nor mention of Idorsia/Mylan.
Don't think Cabotegravir is off the table yet, or other products with ViiV.
https://www.freepatentsonline.com/y2023/0405095.html
Wonder if the deal could have any effect on the AI deal with Idorsia?
Viatris was formed from a merger of Mylan and Upjohn. Mylan sold the original Epi Pen. They diversified from theie autoinjector business during the merger. Interesting old Mylan will be selling an ATRS autoinjector product after years of fighting the generic ATRS Epi-Pen.
Viatris is making a big bet on Selatogrel, hope it works out for them. It won't be a huge money maker for HALO, but a nice steady income, after an initial large stocking of packaged AI/Drug combo for the introduction. Long-term it will give increased credibility for ATRS AI products. With the close collaboration, maybe Helen could make some deals with Viatris up coming products. Of which their upcoming products can easily be seen in the informative Pipeline charts in Viatris latest presentation.
"Viatris bets $350 million upfront on two late-stage drugs from Idorsia"
https://firstwordpharma.com/story/5831429
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
https://newsroom.viatris.com/2024-02-28-Viatris-and-Idorsia-Enter-Into-Significant-Global-Research-and-Development-Collaboration
https://investor.viatris.com/static-files/4ba5a0bf-5ae4-4425-a697-233a95c6c763
Interestingly, at Barclays, I noticed Helen mentioned they are seeking potential partnerships in the "nucleic acid"" and "RNA" arena. Is this the first time she has mentioned these potential partners?
In Barclay's fireside chat Helen mentioned there are 7 wave 4 products in development and the slide set says the same, however we now know that the Cabotegravir (ViiV) is off the table so there are in fact only 6.
Latest Slide Set Feb 2024
https://s28.q4cdn.com/284259014/files/doc_presentation/2024/HALO-Corporate-Deck-February-2024-FINAL.pdf
New competition looming for HALO's epipen AI franchise.
https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm
I think you may be correct. My memory of seeing TED indication might have been from the Horizon deal, which seems to have been abandoned in light of Horizon's newer deal with Xeris.
I think you may be correct. My memory of seeing TED indication might have been from the Horizon deal, which seems to have been abandoned.
Also you can do a word search in their most recent 8k and 10k filings. There is no mention of TED with Efgartigimod (Argenx)
I think you are incorrect. I don’t ever remember, Halozyme having 2 deals with 2 different partners (Horizon and Argenx) for the same indication (Thyroid Eye Disease).
Also there never a phase 1 or phase 2 study of Rhuph20 (or ph20, or hyaulonidase) combined with Efgartigimod (from argenx) in clinicaltrials.gov
There are 151 trials with rhuph20 (including all the old trials whether completed or not)
Go check it out yourself.
Sorry for the confusion. I’m speaking in general terms about injectors. Not specific to this deal. Getting SC delivery to market quicker will make it very tough for competition against Enhanze. That extra year or two makes a huge difference.
Howee, also the study is using a pre-filled syringe, not an auto-injector.
I don't think this is a new deal but one that was originally a part of the original ARGX deal which contained multiple targets including thyroid eye disease. I'm not certain about this, though. I do remember seeing something on the (HALO web site maybe?) about that target long before biotechinvestor posted yesterday. Unfortunately HALO chose to take down that useful chart on the partner pipeline so I can't be sure. Bottom line for me is that I'm not treating it as a new target but rather a pre-existing one that is just getting off the ground.
Great find!!!! This should save and make Partners a lot of money. Maybe this makes doing business with Halo vs any would be competitor a no brainer. Maybe Helen knows what she’s doing after all.
Also until recently I really never paid much attention to the injector market. She is definitely on to something.
Good pickup, thanks for sharing. Efgartigimod should keep HALO afloat for a while unless ARGX fails another trial.
… we now are far more advanced in this indication than we ever were with Horizon.
…They went straight to phase 3 for a new indication with Enhaze. This is what Helen was talking about when she said regulator no longer need non-inferiority data and all they need is PK study.
Expect big PR about this.
2 Brand new studies of Efgartigimod PH20 SC in Adults With Thyroid Eye Disease posted on clinical trials gov for the first time today. One is with a pre-filled syringe.
This is a new indication for Enhanze and Argenx that was not previously disclosed by Halozyme.
https://classic.clinicaltrials.gov/ct2/show/NCT06307613?term=Rhuph20&draw=3&rank=107
https://classic.clinicaltrials.gov/ct2/show/NCT06307626?term=Rhuph20&draw=3&rank=106
Followers
|
103
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8529
|
Created
|
07/24/06
|
Type
|
Free
|
Moderators Fred Kadiddlehopper |
http://www.halozyme.com
Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology, and dermatology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases.
The company's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its first partnership is with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets. In addition, the company has received FDA approval for two products: Cumulase® and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter Healthcare Corporation. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.
Halozyme is a therapeutically driven biopharmaceutical company developing and commercializing recombinant human enzymes to provide enhanced and innovative alternatives that improve the practice of medicine. Halozyme is focused on providing life-saving and life-enhancing solutions to the drug delivery, oncology, and dermatology markets.
Products/Pipeline
Halozyme is a therapeutically driven biopharmaceutical company developing and commercializing recombinant human enzymes to provide enhanced and innovative alternatives that improve the practice of medicine. Halozyme is focused on providing life-saving and life-enhancing solutions to the drug delivery, oncology, and dermatology markets.
The foundation of our capabilities is our recombinant human hyaluronidase enzyme, rHuPH20, which temporarily degrades hyaluronan, a structural protein in the interstitial space. This temporary alteration provides an opportunistic window that allows the delivery of injectable biologics such as monoclonal antibodies, as well as small molecules and fluids. With our enzyme, many pharmaceuticals that would normally be injected intravenously (IV) can be administered subcutaneously (SC). This change in route of delivery may improve patient convenience, enhance pharmacokinetics, boost efficacy, extend the product lifecycle, and reduce cost, in addition to other attributes.
Four key internal programs comprise our current proprietary product development portfolio. The endocrinology franchise consists of Insulin-PH20, which applies our PH20 enzyme to currently approved and marketed insulin products. The oncology franchise consists of PEGPH20, a new molecular entity administered intravenously that targets the external environment of tumor cells, and Chemophase, which utilizes the PH20 enzyme for local administration in bladder cancer. Our lead enzyme in the dermatology franchise, HTI-501, is a new molecular entity which digests collagen and may have applications in both medical and aesthetic dermatology such as cellulite.
Our product development pipeline also includes three distinct partnered programs with two companies; Roche and Baxter BioScience for Enhanze technology, and a partnership with Baxter Medication Delivery for Hylenex, our FDA-approved drug. These partnered programs validate our technology and may generate clinical and commercial milestone revenue based on the achievement of pre-specified events along with sales royalties when products reach the commercial stage. We utilize the cash milestone payments generated from the partnered programs as a source of development funding for our proprietary pipeline projects.
Endocrinology
Our endocrinology development activity focuses on insulin, a mainstay of treatment for people with diabetes. This program combines our PH20 hyaluronidase enzyme with insulin, a frequently prescribed, commercially successful pharmaceutical already approved and on the market.
We believe that the combination of our PH20 enzyme with existing, meal time insulin products such as regular insulin or a fast acting analog could lead to a best-in-class product that more closely mimics the release of natural insulin in the body. The results of a Phase 1 study, where we combined PH20 with Humulin® R (regular human insulin) and with Humalog® (insulin lispro), demonstrated significantly faster and higher insulin plasma concentrations compared to either insulin alone. Faster acting insulin could provide patient benefits such as reduced hypoglycemia, lower intra-subject variability, and less weight gain. These potential benefits would be significant but must first be demonstrated and proven in clinical development.
Our first Phase 2 clinical trial with insulin began in October 2008 and enrolled Type 1 diabetic patients. Data presented from our Phase 1 trial showed that the administration of regular insulin and an insulin analog with our PH20 enzyme led to faster insulin absorption and more rapid effects than either insulin alone. Our Phase 2 trial is designed to demonstrate similar results in Type 1 diabetic patients. We hope to present preliminary Phase 2 results at the American Diabetes Association meeting in June. Additional clinical trials are planned in 2009.
ONCOLOGY
Hyaluronan (HA) is a component of the extracellular matrix that frequently accumulates in human cancers. The quantity of HA produced by the tumor cells directly correlates with increased tumor growth and metastasis and it has been linked with tumor progression and poor prognosis. Previous clinical trials of bovine hyaluronidase showed promise in enhancing chemotherapy regimens using adjunctive systemic hyaluronidase in chemo-refractory patients. In animal studies the removal of HA from tumors with hyaluronidase has demonstrated improved survival, suppression of tumor growth, and enhanced efficacy of certain anti-cancer drugs. Chemotherapeutic agents may be able to better penetrate the tumor once the HA has been removed.
We have also observed significant reduction of tumor interstitial fluid pressure (IFP) following the administration of rHuPH20 in solid tumors grown in mice. Tumor interstitial pressure is widely believed to be an important factor limiting the access of cytostatic regimens to solid tumors. By digesting the HA gel, rHuPH20 may reduce IFP in the tumor and promote more effective delivery of chemotherapy throughout the tumor. This could potentially lead to better patient outcomes and increased survival.
Our PEGPH20 program utilizes pegylated hyaluronidase that allows for intravenous administration to degrade the HA that surrounds tumor cells. The Chemophase program applies the hyaluronidase enzyme along with mitomycin C directly into the bladder where the enzyme can hydrolyze the HA produced by the cancerous bladder cells. Unlike tumor cells, normal cells do not produce HA in this manner and appear not to be adversely affected by the enzyme.
We are investigating pegylated-rHuPH20, or PEGPH20, a new molecular entity, as a candidate for the systemic treatment of tumors rich in hyaluronan, or HA. Pegylation refers to the attachment of polyethylene glycol to our rHuPH20 enzyme, which extends its half life from less than 30 seconds to more than 24 hours. Numerous solid tumors, including prostate, breast, pancreas, colon and non-small cell lung, accumulate HA that forms a halo like coating over the surface of the tumor cell.
In preclinical studies, PEGPH20 has been shown to remove the HA coating surrounding several tumor cell lines. Treatment of PC3 (a prostate cancer cell line that produces HA) tumor bearing mice with PEGPH20 as a single agent demonstrated approximately 70% tumor growth inhibition relative to controls. Repeat dosing with PEGPH20 produced a sustained depletion of HA in the tumor microenvironment. For tumor models that do not produce HA, the presence of PEGPH20 has no effect. An estimated 20% to 40% of certain solid tumors may produce HA.
Administration of the combination of PEGPH20 with docetaxel or with liposomal doxorubicin in HA producing animal tumor models produced a significant survival advantage for the combination relative to either chemotherapeutic agent alone. Therefore, based on these animal studies and other tests conducted by Halozyme, PEGPH20 may represent a potentially innovative treatment approach against tumors that produce HA.
PEGPH20 recently started its first Phase 1 clinical trial which will evaluate the agent over a range of doses. The study will enroll up to 46 advanced cancer patients who will receive treatment cycles of intravenous PEGPH20 as a single agent twice weekly for three weeks followed by one week without dosing. Patients may continue subsequent cycles at their assigned dose as long as there is no tumor progression and no unacceptable toxicity. Groups of four to eight patients will be in each dosage cohort. The primary outcome measures of the study will be to evaluate safety and tolerability of PEGPH20 and to determine the recommended single agent Phase 2 dose. Secondary objectives will be to determine pharmacokinetics, obtain dose limiting toxicities, and observe patients for any evidence of anti-tumor activity.
Chemophase is a chemoadjuvant we have investigated for possible use in the treatment of patients with superficial bladder cancer, which represents a smaller potential market than our other proprietary pipeline opportunities. The Chemophase program combines our PH20 enzyme with mitomycin C, a cytotoxic drug, for direct administration into the bladder immediately after transurethral resection of bladder tumors (TURBT), a standard surgical treatment for the disease. Many bladder tumor cells produce high quantities of HA and thus treatment to remove the HA coating could increase their exposure to mitomycin C. This may lead to a lower recurrence of the cancer and a better prognosis for patients.
In June 2008, we announced the interim results of a Phase I/IIa clinical trial in which the Chemophase combination treatment of mitomycin C plus rHuPH20 enzyme was well tolerated and appears safe. The study reported no dose-limiting toxicities and no observed side effects attributable to the enzyme. An ongoing safety trial involves the immediate post operative (IPOP) administration of PH20 and mitomycin directly into the bladder of patients after a TURBT procedure.
DERMATOLOGY
The foundation of our dermatology program is HTI-501, a human lysosomal proteinase that degrades collagen. It may be useful in the treatment of both medical and aesthetic dermatologic conditions such as cellulite, Dupuytren’s contracture and Peyronie’s disease. This pH sensitive enzyme demonstrates activity under mildly acidic conditions but shows no activity at normal physiologic pH. This attribute may be harnessed to exert control over the duration and location of the enzyme’s therapeutic activity.
Tests with HTI-501 in several animal models have produced encouraging results and our pre-clinical investigations of the enzyme will continue throughout 2009.
ENHANZE
Enhanze™ Technology, a proprietary drug delivery platform using Halozyme’s first approved enzyme, rHuPH20, is our broader technology opportunity that can potentially lead to partnerships with other pharmaceutical companies. When co-formulated with other injectable drugs, Enhanze Technology may facilitate the penetration and dispersion of these drugs by temporarily opening flow channels under the skin.
Molecules as large as 200 nanometers may pass freely through the extracellular matrix, which recovers its normal density within approximately 24 hours, leading to a drug delivery platform which does not permanently alter the architecture of the skin. The principal focus of our Enhanze Technology platform is the use of rHuPH20 to facilitate subcutaneous or intramuscular routes of administration for large molecule biological therapeutics. We are seeking partnerships with pharmaceutical companies that market drugs requiring or benefiting from injection via the subcutaneous or intramuscular routes that could benefit from this technology. In December 2006, we signed our first Enhanze Technology partnership with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche, Inc. In September 2007, we signed our second Enhanze Technology partnership with Baxter Healthcare Corporation and Baxter Healthcare S.A.
HYLENEX
Full prescribing information is available below or at www.hylenex.com
Hylenex is a human recombinant formulation of rHuPH20 to facilitate the absorption and dispersion of other injected drugs or fluids. When injected under the skin or in the muscle, hyaluronidase can digest the hyaluronic acid gel, allowing for temporarily enhanced penetration and dispersion of other injected drugs or fluids. We filed a New Drug Application (NDA) in March 2005 and we received approval of our Hylenex NDA in December 2005.
Hylenex may facilitate subcutaneous delivery of fluids up to one liter without the need for intravenous access, a procedure known as EASI. Importantly, EASI for fluid replacement in terminal patients may be achieved with limited or no need for nursing assistance. Over 1.1 million subcutaneous fluid infusions are performed per year with hospice patients alone (Source: Company estimates based on National Hospice and Palliative Care Organization data, 2001). In addition, over 500 million infusion bags are utilized annually in the United States, some of which could potentially convert to EASI using Hylenex, giving rise to additional market potential (Source: B. Braun, 2003).
During January 2006, we completed the INcreased Flow Utilizing Subcutaneously-Enabled Lactated Ringer’s clinical trial, or INFUSE-LR study, which was designed to determine the subcutaneous (Sub-Q) infusion flow rate of Lactated Ringer’s solution with and without Hylenex, determine the Sub-Q infusion flow rate dose response to Hylenex over one order of magnitude of dose, and assess safety and tolerability. This prospective, double-blind, randomized, placebo-controlled, within-subject, dose-comparison study enrolled 54 volunteer subjects who received Sub-Q infusions simultaneously in both upper arms through 24 gauge catheters.
During October 2006, we completed the INcreased Flow Utilizing Subcutaneously-Enabled Morphine clinical trial, or INFUSE-Morphine study, which was designed to determine the time to maximal blood levels of morphine after subcutaneous administration with and without Hylenex, to determine the time to maximal blood levels after intravenous administration of morphine, and to assess safety and tolerability. This prospective, double-blind, randomized, placebo-controlled, within-subject, dose-comparison study enrolled 12 evaluable patients who received Sub-Q infusions.
For full prescribing information, visit www.hylenex.com or www.baxter.com.
CUMULASE
Cumulase is an ex vivo (used outside of the body) formulation of rHuPH20 to replace the bovine enzyme currently used for the preparation of oocytes (eggs) prior to IVF during the process of intracytoplasmic sperm injection (ICSI), in which the enzyme is an essential component. The enzyme strips away the hyaluronic acid that surrounds the oocyte. This allows the clinician to then perform the ICSI procedure, injecting the sperm into the oocyte. The FDA considers hyaluronidase IVF products to be medical devices subject to 510(k) approval and we filed our 510(k) application during September 2004.
We received FDA clearance in April 2005. We launched Cumulase in the European Union and in the United States in June 2005. We believe the total ICSI market consisted of an estimated 500,000 intracytoplasmic sperm injection cycles worldwide in 2005 (Source: CDC, 2001; ESHRE, 2002).
Visit www.cumulase.com for more information.
Informative Links
http://www.nasdaq.com/asp/Holdings.asp?FormType=Institutional&page=holdingssymbol=HALO&selected=HALO
(Institutional Holdings)
http://www.cnbc.com/id/15837275?q=HALO
(Big Block Holders from CNBC)
http://www.sec.gov/edgar/searchedgar/companysearch.html
(SEC filings search from SEC.gov Edgar)
http://www.nasdaqtrader.com/Trader.aspx?id=shortinterest (Short Interest)
http://www.newratings.com/main/search_result.m?section=search
(Analyst Ratings)
http://www.insidercow.com/history/company.jsp?company=HALO&B1=Search%21
(Insider Transactions)
http://clinicaltrials.gov/ct2/results?term=rhuph20
http://clinicaltrials.gov/ct2/results?term=hyaluronidase+%28human+recombinant%29
(Clinical Trials)
Clinicals & Partners
http://media.corporate-ir.net/media_files/irol/17/175436/120506RocheHalozymePR.pdf
Halozyme and Roche enter agreement for the application of Enhanze, a novel technology to improve drug delivery
http://media.corporate-ir.net/media_files/irol/17/175436/RocheHalozymeSCRIPPresentation.pdf
(Halozyme and Roche presents “Developing and Managing Strategic Alliances” at the SCRIP conference
May 15-16, 2007 Berlin, Germany)
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1049931&highlight=
Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
http://www.genengnews.com/news/bnitem.aspx?name=32185399
Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously (Enhanze 3-16-08)
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=962993&highlight=
Halozyme and Baxter Expand Global HYLENEX Collaboration
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=IROL-secToc&TOC=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvY29udGVudHMueG1sP2lwYWdlPTU0NDgxMjkmcmVwbz10ZW5r (Feb. 12, 2008 Slide Show Presentation)
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1093211&highlight=
Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1117082&highlight=
Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1130327&highlight=
Halozyme Therapeutics Presents Pre-Clinical Studies on Dermal Remodeling With HTI-501, a Lysosomal Proteinase
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1147853&highlight=
http://www.baxter.com/about_baxter/news_room/news_releases/2008/03-16-08-gammagard_liquid.html
Phase I/II data showed that Enhanze Technology™ enabled subcutaneous administration of a monthly dose of GAMMAGARD LIQUID in patients with Primary Immunodeficiency
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1163612&highlight=Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
Cheetah full ADA presentation
http://www.halozyme.com/images/ADA%202008%20Poster%20legal.pdf
Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1177539&highlight=
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1170737&highlight=
Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1220870&highlight=
Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1233454&highlight=
Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1234643&highlight=
Halozyme Deprioritizes Bisphosphonate Program to Reallocate Resources to More Commercially Attractive Internal Programs
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1295922&highlight=
Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1240232&highlight=
Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial With Second Biologic
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1244971&highlight=
Halozyme Therapeutics Presents Positive Pre-Clinical Single Agent Data for PEGPH20
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1248119&highlight=
AACR presentations show that PEGPH20 produces anti-cancer activity in models of breast, prostate, and brain metastases that produce hyaluronan
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1277960&highlight=
Phase 1 Study for Halozyme's Insulin-PH20 Published, Highlights Findings for Faster Acting Insulin Formulations |
|
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1293715&highlight=
Accelerated Insulin Pharmacokinetics and Improved Glycemic Control in T1DM Patients by
Coadministration of Prandial Insulin with Recombinant Human Hyaluronidase
http://www.halozyme.com/ADA%202009%20Poster%20v3%202.pdf
Halozyme Announces Roche Selects Fifth Exclusive Biologic Target
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1297519&highlight
Baxter and Halozyme Announce Completion of Patient Enrollment in Phase III Pivotal Trial of GAMMAGARD LIQUID(TM) with rHuPH20 Enzyme
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1307856&highlight=
First patient dosed in trial with third Roche biologic formulated with Halozyme’s recombinant human hyaluronidase enzyme
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1330295&highlight=
Baxter Announces the Commercial Launch of HYLENEX at ACEP for Use in Pediatric Rehydration |
Data from the First Pediatric Rehydration Study, INFUSE-PEDS 1, Published Today in Pediatrics |
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1338559&highlight=
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R)
http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1344910&highlight=
Earnings Transcripts
http://seekingalpha.com/article/68609-halozyme-therapeutics-q4-2007-earnings-call-transcript?source=yahoo&page=1
Halozyme Therapeutics Q4 2007 Earnings Call Transcript
http://seekingalpha.com/article/76655-halozyme-therapeutics-inc-q1-2008-earnings-call-transcript?source=yahoo
Halozyme Therapeutics Inc. Q1 2008 Earnings Call Transcript
http://seekingalpha.com/article/90080-halozyme-therapeutics-inc-q2-2008-earnings-call-transcript?source=yahoo&page=1
Halozyme Therapeutics Inc. Q2 2008 Earnings Call Transcript
http://seekingalpha.com/article/106797-halozyme-therapeutics-inc-q3-2008-earnings-call-transcript?source=yahoo
Halozyme Therapeutics, Inc. Q3 2008 Earnings Call Transcript
http://seekingalpha.com/article/125929-halozyme-therapeutics-inc-q4-2008-earnings-call-transcript?source=trans_sb_previous
Halozyme Therapeutics, Inc. Q4 2008 Earnings Call Transcript
http://seekingalpha.com/article/171883-halozyme-therapeutics-inc-q3-2009-earnings-call-transcript?source=yahoo
Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript
Links to understanding Clinical results
http://www.boomer.org/c/p3/c02/c0210.html
http://health.yahoo.com/other-other/picomoles-per-liter-pmol-l/healthwise--stp1694.html
http://www.unc.edu/~rowlett/units/scales/clinical_data.html
http://www.bio.net/bionet/mm/immuno/2000-July/015983.html
http://www.boomer.org/c/p1/
http://www.merck.com/mmpe/sec20/ch303/ch303a.html
Shares Outstanding: 91,095,288
Float: 73.21M
http://www.deepcapture.com/
(O-T How the market is manipulated and companies destroyed)
Halozyme Therapeutics Inc.
11588 Sorrento Valley Road
Suite 17
San Diego, CA 92121
United States
Phone: 858-794-8889
Halozyme Contact
Robert H. Uhl
Senior Director Investor Relations
858.704.8264
ruhl@halozyme.com
(Disclaimer) Do your own DD and confirm anything said on this board.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |